Clinical trial of citalopram in cocaine dependence

$241,677P50FY2011DANIH

University Of Texas Hlth Sci Ctr Houston, Houston TX

Investigators

Linked publications, trials & patents

Paper 37344702 Paper 36971714 Paper 36614248 Paper 34994673 Paper 34923324 Paper 34600245 Paper 33119414 Paper 33021143 Paper 32593950 Paper 32267062 Paper 31958903 Paper 31927220 Paper 31631955 Paper 31176066 Paper 30968959 Paper 30625144 Paper 30472571 Paper 30418104 Paper 30408130 Paper 29771557 Paper 29287668 Paper 28498501 Paper 28192722 Paper 27862692 Paper 27646197 Paper 27022201 Paper 27014100 Paper 26693170 Paper 26681735 Paper 26566718 Paper 26512421 Paper 26484829 Paper 26241153 Paper 26170765 Paper 26164486 Paper 26110342 Paper 26082893 Paper 25841982 Paper 25662909 Paper 25414797 Paper 25336321 Paper 25299617 Paper 25134057 Paper 24809448 Paper 24621090 Paper 24618688 Paper 24582546 Paper 24512640 Paper 24507117 Paper 24424425 Paper 24029622 Paper 24026715 Paper 23761390 Paper 23588313 Paper 23549451 Paper 23371492 Paper 23151990 Paper 22969732 Paper 22905331 Paper 22654774 Paper 22464943 Paper 22425411 Paper 22047976 Paper 21730016 Paper 21692148 Paper 21204739 Paper 21172570 Paper 20661285 Paper 20570057 Paper 20545388 Paper 20478631 Paper 20155594 Paper 20153142 Paper 19595517 Paper 19462304 Paper 19353809 Paper 19322730 Paper 19217266 Paper 19058926 Paper 18164144 Paper 18093749 Paper 17994474 Paper 17613964 Paper 17543472 Paper 17321725 Paper 17134849 Paper 16966192 Trial NCT02774343 Trial NCT02080832 Trial NCT01535573 Trial NCT00783276 Trial NCT00733993 Trial NCT00514202 Trial NCT00439049 Trial NCT00218075 Trial NCT00218062 Trial NCT00218036 Trial NCT00218023 Trial NCT00217997 Trial NCT00000305

Abstract

Selective serotonin reuptake inhibitors (SSRIs) have been a focus of research in development of medication for cocaine dependence, in part because preclinical studies have shown that manipulation of the serotonin (5-HT) system affects cocaine self administration and drug reinstatement. Some of the strongest human data supporting examination of one particular SSRI for cocaine dependence comes from a clinical trial completed by our research group. In a preliminary 12-week, double blind, placebo controlled trial of citalopram for cocaine dependence, citalopram produced a significant reduction in cocaine positive urines compared to placebo. Based on what is known regarding the role of the orbito-frontal cortex (OFC) and striatum in addiction and the effects of 5-HT manipulation on OFC function, there is evidence supporting the hypothesis that the reduction in cocaine use achieved by citalopram is related to change in striatal dopamine function mediated in part by changes in OFC serotonin. Combined with the positive preliminary findings from our previous clinical study with citalopram, this provides a strong rationale for further studies of citalopram as a treatment for cocaine dependence. This study builds upon compelling evidence supporting citalopram as a treatment medication for cocaine dependence, based on a conceptual model of prefrontal-striatal interactions. In the context of a randomized, double-blind, placebo-controlled, intent-to-treat, 3-arm, parallel design, single site study, with a sample size of N=125 cocaine dependent subjects, we expect to confirm the hypothesis that citalopram reduces cocaine use during treatment and increases abstinence rates at the end of treatment compared to placebo. Secondary analyses will test behavioral markers as predictors of treatment response based on the conceptual model of citalopram on fronto-striatal function.

View original record on NIH RePORTER →